Pfizer signs immunotherapy deal with Cellectis


Pfizer (PFE) has signed a deal with French biotech firm Cellectis to develop immunotherapy drugs for cancer. The latter is developing Chimeric Antigen Receptor T-cell immunotherapies using engineered cells from a single donor for use in multiple patients.

The agreement includes an an initial lump sum of $80M, as well as payment allocated towards research costs. Cellectis will also be entitled to receive development, regulatory and commercial milestone payments of up to $185M per Pfizer product, and royalties on any eventual sales.

Pfizer is also purchasing a 10% stake in Cellectis through newly issued €9.25 shares.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs